(Q38821729)

6 September 2017

title

Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance (English)

1 reference

6 September 2017

0 references

1 reference

Katherine Ferrara

6

0 references

author name string

Dipali Patel

1

1 reference

6 September 2017

Yandong Gao

2

1 reference

6 September 2017

Kyungjin Son

3

1 reference

6 September 2017

Christian Siltanen

4

1 reference

6 September 2017

Richard M Neve

5

1 reference

6 September 2017

Alexander Revzin

7

1 reference

6 September 2017

language of work or name

1 reference

6 November 2015

1 reference

6 September 2017

1 reference

6 September 2017

volume

15

1 reference

6 September 2017

issue

24

1 reference

6 September 2017

page(s)

4614-4624

1 reference

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Mechanisms of acquired resistance to targeted cancer therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Therapy-induced tumour secretomes promote resistance and tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

FGF receptors: cancer biology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Cellular observations enabled by microculture: paracrine signaling and population demographics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Controlling cell interactions by micropatterning in co-cultures: hepatocytes and 3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Directing hepatic differentiation of embryonic stem cells with protein microarray-based co-cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Micropatterned co-cultures of T-lymphocytes and epithelial cells as a model of mucosal immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Microfabrication of hepatocyte/fibroblast co-cultures: role of homotypic cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

A versatile valve-enabled microfluidic cell co-culture platform and demonstration of its applications to neurobiology and cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Co-culture of neurons and glia in a novel microfluidic platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Reconfigurable microfluidics with integrated aptasensors for monitoring intercellular communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Using reconfigurable microfluidics to study the role of HGF in autocrine and paracrine signaling of hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Prediction of diffusion coefficients of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Photodegradable hydrogels for capture, detection, and release of live cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

The role of MEK inhibitors in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

MAP kinase signaling and inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Efficient production and purification of extracellular domain of human FGFR-Fc fusion proteins from Chinese hamster ovary cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC5LC00948K

21 January 2018

Identifiers

DOI

10.1039/C5LC00948K

1 reference

6 September 2017

1 reference